More on CYTR

- Summary
- Chart
- Profile
- Historical


- Earnings (-10.0% Growth)
- Ratings (8.3 Score)
- Holders


Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (2/4/16 *Est.)


- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks

CYTR Balance Sheet

Click line-items for a historical chart and %
Current assets:
Cash and cash equivalents 55.78M
Marketable securities 15.02M
Proceeds from sale of RXi, received January 6, 2011
Receivable 1.67M
Investment in Adventrx Pharmaceuticals, at market
Income taxes recoverable
Interest receivable 6.75K
Prepaid expenses and other current assets 1.46M
Total current assets 73.94M
Equipment and furnishings, net 1.06M
Goodwill 183.78K
Other assets 1.57M
Total assets 76.75M
Current liabilities:
Accounts payable 6.21M
Accrued expenses and other current liabilities 5.97M
Warrant liabilities 1.05M
Total current liabilities 13.23M
Stockholders' equity:
Preferred Stock, $.01 par value, 5,000,000 shares authorized, including 15,000 shares of Series A Junior Participating Preferred Stock; no shares issued and outstanding 0
Common stock, $.001 par value, 175,000,000 shares authorized; 109,857,885 and 109,840,445 shares issued and outstanding at June 30, 2011 and December 31, 2010, respectively 66.68K
Additional paid-in capital 408.86M
Accumulated comprehensive income, net of tax
Treasury stock, at cost (633,816 shares) -2.61M
Accumulated deficit -342.79M
Total stockholders' equity 63.52M
Total liabilities and stockholders' equity 76.75M